Akari Therapeutics Files 8-K on Financials
Ticker: AKTX · Form: 8-K · Filed: May 16, 2024 · CIK: 1541157
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: AKTX
TL;DR
AKTX filed an 8-K today detailing financial results and condition.
AI Summary
Akari Therapeutics Plc filed an 8-K on May 16, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 22 Boston Wharf Road, Boston, MA.
Why It Matters
This filing provides crucial updates on Akari Therapeutics' financial health and operational results, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- May 16, 2024 (date) — Date of earliest event reported
- 22 Boston Wharf Road FL 7 Boston, MA 02210 (address) — Principal Executive Offices
- Celsus Therapeutics Plc. (company) — Former Company Name
- Morria Biopharmaceuticals PLC (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for Akari Therapeutics Plc?
The primary purpose is to report on the company's Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.
On what date was this 8-K filing reported?
The date of the earliest event reported is May 16, 2024.
Where are Akari Therapeutics Plc's principal executive offices located?
The principal executive offices are located at 22 Boston Wharf Road, FL 7, Boston, MA 02210.
What were Akari Therapeutics Plc's former company names?
The company was formerly known as Celsus Therapeutics Plc. and Morria Biopharmaceuticals PLC.
What is the SEC file number for Akari Therapeutics Plc?
The SEC file number is 001-36288.
Filing Stats: 589 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-05-16 08:05:16
Key Financial Figures
- $0.0001 — tal Market Ordinary Shares, par value $0.0001 per share* *Trading, but only in conn
Filing Documents
- aktx-20240516.htm (8-K) — 46KB
- aktx-ex99_1.htm (EX-99.1) — 105KB
- 0000950170-24-060806.txt ( ) — 381KB
- aktx-20240516.xsd (EX-101.SCH) — 95KB
- aktx-20240516_htm.xml (XML) — 6KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 16, 2024, Akari Therapeutics, Plc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024 and certain other information. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information furnished pursuant to this Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 16, 2024, of Akari Therapeutics, Plc. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: May 16, 2024 By: /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. Interim President and Chief Executive Officer